Nanomedicines for paediatric osteosarcoma treatment

Orateur : María J. BLANCO-PRIETO (University of Navarra, Pamplona, Spain)

Osteosarcoma (OS) is the most frequent primary bone tumor in the pediatric population and one of the most frequent causes of pediatric cancer death. Primary OS develops in large bones with high growth potential such as the femur, tibia or humerus ; however OS must be considered a systemic disease because although at diagnosis 20% of the patients present visible lung metastasis, micrometastatic or circulating disease is assumed in nearly all patients. Despite the combination of several cytotoxic drugs including doxorubicin, cisplatin or isofosfamide the 5-year survival for those patients with detectable metastasis is still 10-30%. Therefore, new therapies are urgently needed to improve the disease prognosis. Edelfosine is the prototype of a promising class of antitumor agents that do not target the DNA and has shown efficacy in several cancer cell lines. Among colloidal carriers, lipid nanoparticles (LN) have arisen as suitable candidates for the delivery of edelfosine, as they are able to solubilize lipophilic drugs and provide an absorption enhancing effect in the intestinal tract. The focus of this talk will be mainly to discuss the efficacy of edelfosine-loaded LN orally administered for the treatment of osteosarcoma. Emphasis will be placed on :

Télécharger dans mon agenda